Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 3, 2018. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
| Metric | Value |
|---|---|
| Issued Ordinary Shares (as of March 29, 2018) | 5,373,568,273 |
| Share Par Value | 25 pence each |
| Treasury Shares | 414,605,950 |
| Total Voting Rights | 4,958,962,323 |
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It provides a static snapshot of the share capital structure as of March 29, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The primary purpose is to inform shareholders of the denominator to be used for calculating notification thresholds under the Financial Conduct Authority's rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,958,962,323) against the issued share count minus treasury shares.
- Confirm the date of the share capital snapshot (March 29, 2018) for regulatory compliance calculations.
- Note that this filing does not contain financial performance data; refer to Form 20-F for quarterly or annual financial results.